ISPOR Roadmap for Patient-Preference Studies in Decision Making
This guideline helps researchers and decision makers design and use patient-preference studies so that patient voices are better included in healthcare decisions made by regulators, payers, and health technology assessment bodies.
At a glance
Use when
Designing or evaluating patient-preference studies for use in regulatory submissions, HTA dossiers, or payer negotiations
Avoid when
Patient preferences are not relevant to the decision context or when robust patient input cannot be obtained
Inputs
Patient input, clinical context, study objectives, stakeholder requirements, preference elicitation methods
Outputs
Structured patient-preference evidence suitable for regulatory, HTA, and payer decision making
How it works
Developed by the ISPOR Patient Preferences Task Force (2023), this roadmap provides good-practice recommendations for conducting and applying patient-preference studies across the product lifecycle. It supports cross-stakeholder (regulatory, HTA, payer) decision making by enhancing methodological rigor, transparency, and relevance of preference data.
- HTA domains
- Clinical Effectiveness, Organisational aspects, Patient and Social Aspects
- Assumptions
- Patient preferences can be systematically measured and are relevant to healthcare decision making across stakeholders
- Strengths
- Promotes methodological consistency, supports multi-stakeholder acceptance, enhances patient-centeredness in evaluations
- Limitations
- May require specialized expertise to implement; applicability depends on disease and intervention context
- Also known as
- ISPOR Patient Preference Roadmap, ISPOR Task Force Roadmap on Patient Preferences
Questions this answers
- › How can patient preferences be reliably measured and integrated into healthcare decision making?
- › What methodological standards should be followed in patient-preference studies?
- › How can preference studies be designed to meet the needs of regulators, HTA bodies, and payers?
- › What are best practices for stakeholder engagement in preference research?
- › When and how should patient preference data be submitted to decision-making bodies?
- › How can the impact of patient preference evidence be maximized in HTA and regulatory contexts?
References & sources
Similar by meaning
- IMI PREFER Framework and Recommendations
- ISPOR Quantitative Benefit-Risk Assessment Good Practices
- ISPOR Conjoint Analysis Experimental Design Good Research Practices
- ISPOR Prospective Observational Studies to Assess Comparative Effectiveness Good Research Practices Task Force Report
- ISPOR Statistical Methods for the Analysis of Discrete-Choice Experiments
Beta record. Based on the original catalogue summary; primary-source enrichment pending.